SNPs associated with colorectal cancer and uses therof

The use of MMP14 and MKLN1 gene SNPs, particularly rs3751489 and rs75170436, addresses the challenge of low diagnostic accuracy in colorectal cancer by providing a reliable genetic marker for early detection and improved treatment.

KR103044294B1Active Publication Date: 2026-11-06SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020240196750
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-12-26
Publication Date
2026-11-06
Estimated Expiration
2044-12-26

AI Technical Summary

Technical Problem

Current diagnostic methods for colorectal cancer have low accuracy and cannot detect the disease before metastasis, leading to unsatisfactory treatment outcomes, and there is a need for biomarkers to predict or diagnose colorectal cancer onset.

Method used

A marker composition comprising single-nucleotide polymorphisms (SNPs) of the MMP14 and MKLN1 genes, specifically rs3751489 and rs75170436, is used to predict or diagnose colorectal cancer through genetic analysis.

Benefits of technology

The SNPs provide a reliable method for predicting or diagnosing colorectal cancer by identifying genetic markers associated with the disease, enhancing early detection and improving treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024144120248-PAT00005_ABST
    Figure 112024144120248-PAT00005_ABST
Patent Text Reader

Abstract

The present invention relates to single nucleotide polymorphisms associated with the development of colorectal cancer and their uses. In the present invention, single nucleotide polymorphism sites are extracted from the genomes of a group of colorectal cancer patients, and beta values ​​are calculated through logistic regression analysis based on single nucleotide polymorphism sites. By performing biological analysis, single nucleotide polymorphisms within specific genes that show a statistically significant association with the development of colorectal cancer selected can be utilized for the prediction or diagnosis of colorectal cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a single nucleotide polymorphism associated with the development of colorectal cancer and its uses. Background Technology

[0002] Pathologically, most colorectal cancers are adenocarcinomas, and they are broadly classified into colon cancer and rectal cancer by location. In terms of incidence by location, the lower colon, or rectum, accounts for the highest proportion at approximately 50%. According to recent research results, changes in dietary habits have led to a significant increase in the incidence and associated mortality rates of colorectal cancer in Korea. Furthermore, according to the WHO, the total population diagnosed with cancer over the past 20 years nearly doubled from 10 million in 2000 to 19.3 million in 2020, and these numbers are expected to rise further in the future. According to a report published by the National Cancer Center in 2020 (National Cancer Center, Cancer Trends Report 2020), colorectal cancer is the second most common cancer (12.1%) after gastric cancer, and its mortality rate is reported to be the third highest among all types of cancer. Although the exact cause of colorectal cancer is still unclear, genetic factors, dietary habits involving the intake of high-fat and low-fiber foods, and inflammatory bowel disease are considered as contributing factors. Colorectal cancer can occur at any age, but the incidence increases with age, frequently occurring in people in their 50s and 60s. Regarding gender ratios, colon cancer occurs slightly more frequently in women, while rectal cancer occurs slightly more frequently in men.

[0003] Most cancer patients, including those with colorectal cancer, die primarily as a result of metastasis, even when utilizing various existing treatment methods (surgery, chemotherapy, and radiation therapy). While the probability of successful treatment is high for most patients where a primary tumor is observed before metastasis occurs, such patients are difficult to detect, and in most patients, metastasis is already detected at the time the primary tumor is observed. Since most cancer metastases are multifocal and systemic, and determining their presence is difficult, the efficacy of current cancer treatment methods is unsatisfactory. Diagnosis of colorectal cancer is performed by digital rectal examination, stool occult blood test, and barium enema in patients exhibiting symptoms related to the colon; if necessary, sigmoidoscopy and biopsy via colonoscopy are performed. However, these conventional methods not only have low diagnostic accuracy but also make early diagnosis impossible for patients before the onset of colorectal cancer and cause discomfort to the subjects. Therefore, there is an urgent need to discover biomarkers that can serve as indicators for the treatment and diagnosis of cancer, such as its occurrence and metastasis.

[0004] Meanwhile, the genomes of all organisms undergo spontaneous mutations during the process of evolution that produce variants in the sequences of their offspring (Gusella, Ann. Rev. Biochem. 55, 831-854, 1986). These variants may provide evolutionary advantages or disadvantages compared to the offspring form, or they may be neutral. In some cases, the variant causes a lethal disadvantage and is not passed on to offspring. In other cases, it provides an evolutionary advantage to the species, and eventually, the DNA is inserted into the majority of the species, effectively becoming the ancestral form. In many cases, this ancestral form and its variants survive and coexist within the species population. The coexistence of multiple sequence forms gives rise to polymorphism. Known types of such polymorphism include restriction fragment length polymorphisms (RFLP), short tandem repeats (STR), and single nucleotide polymorphisms (SNP). Among these, SNPs take the form of single nucleotide variations between individuals of the same species. When SNPs occur in coding region sequences, a defective or mutated protein may be expressed due to one of the polymorphic forms. In other cases, SNPs may occur in non-coding region sequences, and some of these may induce the expression of defective or mutated proteins (e.g., as a result of defective splicing). Some SNPs may not affect the phenotype. SNPs are known to occur at a frequency of about once every 1,000 bp in humans. If these SNPs affect a phenotype such as a disease, the SNPs can be used as markers to diagnose such diseases.Currently, various research institutions are conducting studies on single nucleotide analysis and its functional analysis, and are database-publishing the nucleotide sequences of identified SNPs and other experimental results. However, in the majority of cases, these studies merely discovered the existence of SNPs on the human genome or cDNA, without elucidating their effects on phenotype. The problem to be solved

[0005] The objective of the present invention is to provide a marker composition for predicting or diagnosing the onset of colorectal cancer.

[0006] In addition, the present invention provides a composition for predicting or diagnosing the onset of colorectal cancer.

[0007] In addition, the present invention provides a kit for predicting or diagnosing the onset of colorectal cancer.

[0008] In addition, the present invention provides a method for providing information for predicting or diagnosing the onset of colorectal cancer. means of solving the problem

[0009] To achieve the above objective, the present invention provides a marker composition for predicting or diagnosing colorectal cancer, comprising a single-nucleotide polymorphism (SNP) of the MMP14 (matrix metalloproteinase-14) gene.

[0010] In addition, the present invention provides a composition for predicting or diagnosing the onset of colorectal cancer comprising a polynucleotide containing a single nucleotide polymorphism of the MMP14 gene or a polynucleotide complementary thereof.

[0011] In addition, the present invention provides a kit for predicting or diagnosing the onset of colorectal cancer comprising the above composition.

[0012] In addition, the present invention provides a method for providing information for predicting or diagnosing the onset of colorectal cancer. Effects of the invention

[0013] In the present invention, single nucleotide polymorphism sites were extracted from the genomes of a group of colorectal cancer patients, beta values ​​were calculated through logistic regression analysis based on single nucleotide polymorphism sites, and biological analysis was performed using gene regulatory function and gene expression information analysis to select single nucleotide polymorphisms within specific genes that are statistically significantly associated with the onset of colorectal cancer, so this can be used for the prediction or diagnosis of colorectal cancer. Brief explanation of the drawing

[0014] Figure 1 is a diagram showing the analysis flowchart of the present invention. Figure 2 shows the Manhattan plot of the Genome-wide Association Study (GWAS). Figure 3 shows the results of performing GTEx (Genotype-Tissue Expression) analysis on colon tissue. Specific details for implementing the invention

[0015] Hereinafter, the present invention will be described in detail with reference to the attached drawings for embodiments of the present invention. However, the following embodiments are presented as examples of the present invention, and if it is determined that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the essence of the present invention, such detailed description may be omitted, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the scope of the claims set forth below and the equivalents interpreted therefrom.

[0016] Furthermore, the terminology used in this specification is used to appropriately describe preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs. Accordingly, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, unless specifically stated otherwise, this means that it does not exclude other components but may include additional components.

[0017] All technical terms used in this invention, unless otherwise defined, are used in the sense generally understood by those skilled in the art in the relevant field of this invention. Additionally, while preferred methods or samples are described herein, similar or equivalents are also included within the scope of this invention. The contents of all publications cited as references in this specification are incorporated into this invention.

[0019] In one aspect, the present invention relates to a marker composition for predicting or diagnosing colorectal cancer, comprising a single-nucleotide polymorphism (SNP) of the MMP14 (matrix metalloproteinase-14) gene.

[0020] In one embodiment, the single nucleotide polymorphism of the MMP14 gene may be a single nucleotide polymorphism of the dbSNP database rs3751489, and may be the rs3751489 G>A polymorphism corresponding to the 1292nd nucleotide of the nucleotide sequence indicated by SEQ ID NO. 1.

[0021] In one embodiment, the marker composition may further include a single nucleotide polymorphism present in an intron of the MKLN1 (muskelin 1) gene, which may be a single nucleotide polymorphism of the dbSNP database rs75170436, and may be an rs75170436 T>C or rs75170436 T>G polymorphism.

[0022] In the present invention, the term “single nucleotide polymorphism (SNP)” refers to a genetic polymorphism in which a single nucleotide is inserted, lost, or substituted in DNA, which occurs with a frequency of at least 1% in a population. Each polymorphism is also known to a person skilled in the art and is a designated unique identifier (“reference SNP”, “refSNP”, or “rs#”) used in the Single Nucleotide Polymorphism Database (dbSNP) of Nucleotide Sequence Variation, which is available, for example, on the NCBI website.

[0023] In the present invention, the term “genotype” refers to a specific allele of a specific gene in a cell or tissue sample, and “allele” or “allele” refers to one of two or more alternative forms of a gene occupying the same chromosomallocus.

[0024] In one aspect, the present invention relates to a composition for predicting or diagnosing colorectal cancer development comprising a preparation capable of detecting or amplifying a single nucleotide polymorphism of the MMP14 gene.

[0025] In one embodiment, the single nucleotide polymorphism of the MMP14 gene may be a single nucleotide polymorphism of the dbSNP database rs3751489, and may be the rs3751489 G>A polymorphism corresponding to the 1292nd nucleotide of the nucleotide sequence indicated by SEQ ID NO. 1.

[0026] In one embodiment, a preparation capable of detecting or amplifying a single base polymorphism may be a probe capable of binding to the single base polymorphism or a primer capable of specifically amplifying it, and may include a probe or primer capable of detecting or amplifying a polynucleotide containing the single base polymorphism or a polynucleotide complementary thereof.

[0027] In one embodiment, a preparation capable of detecting or amplifying a single nucleotide polymorphism may be a probe or primer comprising a polynucleotide consisting of 8 to 100 consecutive nucleotides including the 1292nd nucleotide of the nucleotide sequence represented by SEQ ID NO. 1 or a polynucleotide complementary thereof, or a microarray comprising a polynucleotide consisting of 8 to 100 consecutive nucleotides including the 1292nd nucleotide of the nucleotide sequence represented by SEQ ID NO. 1 or a polypeptide encoded by the same or its cDNA.

[0028] In one embodiment, the probe or primer is for polymerase chain reaction (PCR), ligase chain reaction (LCR), Gap-LCR, repair chain reaction, transcription-mediated amplification (TMA), self-sustained sequence replication, selective amplification of target polynucleotide sequences, consensus sequence primed PCR (CP-PCR), arbitrary primed PCR (AP-PCR), nucleic acid sequence based amplification (NASBA), strand displacement amplification, loop-mediated isothermal amplification (LAMP), multiplex PCR, nested-PCR, single-tube nested-PCR, reverse transcription PCR (RT-PCR), reverse It can be used for PCR (inverse PCR), real-time PCR, and real-time quantitative PCR (RQ-PCR), dPCR (Digital PCR), or TaqMan-based real-time qPCR.

[0029] In one embodiment, the composition may further include a preparation capable of detecting or amplifying the single nucleotide polymorphism rs75170436 of the MKLN1 gene, and may include a primer, probe, or microarray capable of detecting or amplifying a polynucleotide containing the single nucleotide polymorphism or a polynucleotide complementary thereof.

[0030] The probes or primers of the present invention may be chemically synthesized using the phosphoramidite solid support method or other widely known methods. These nucleic acid sequences may also be modified using many means known in the art. Non-limiting examples of such modifications include methylation, capping, substitution with one or more analogs of the natural nucleotide, and modification between nucleotides, for example, modification to uncharged linkages (e.g., methyl phosphonate, phosphotriester, phosphoroamidate, carbamate, etc.) or charged linkages (e.g., phosphorothioate, phosphorodithioate, etc.). Modifications to the nucleic acid / nucleotide structure may be imparted before or after the assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. The polynucleotides may be further modified after polymerization, such as by binding with labeling components. Other types of modifications include, for example, "caps", replacement of one or more naturally occurring nucleotides with analogs, internucleotide modifications, for example, uncharged linkages (e.g., methylphosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and charged linkages (e.g., phosphorothioates, phosphodithioates, etc.), those containing pendant moiety, for example, those containing pendant moiety such as in proteins (e.g., nucleases, toxins, antibodies, signal peptides, ply-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those with chelators (e.g., metals, radioactive metals, boron, metal oxides, etc.), those containing alkylating agents, modified linkages (e.g., alpha-anomer nucleic acids, etc.) and polynucleotide(s) in their unmodified forms. In addition, any hydroxyl group typically present in the sugar can be replaced, for example, with a phosphonate group or a phosphate group, protected by a standard protection group or activated to prepare for further linkage to an additional nucleotide, or bound to a solid support.The 5' and 3' terminal OH groups may be phosphorylated or replaced with an amine or an organic capping group portion of 1 to 20 carbon atoms. Other hydroxyls may also be derived into standard protecting groups. The polynucleotide may also contain similar forms of ribose or deoxyribose sugars generally known in the art, including, for example, 2'-O-methyl-2'-O-allyl, 2'-fluoro- or 2'-azido-ribose, carbon-cyclic sugar analogs, α-anomer sugars, epimeric sugars such as arabinose, xylose or lyxo, pyranose sugars, furanose sugars, sedoheptulose, acyclic analogs, and basic nucleoside analogs such as methyl riboside. One or more phosphodiester linkages may be replaced with alternative linkers. These alternative linkers include, but are not limited to, configurations in which the phosphate can be replaced with P(O)S ("thioate"), P(S)S ("dithioate"), "(O)NR2 ("amidate"), P(O)R, P(O)OR', CO, or CH2 ("formacetal"), wherein each R or R' is independently a substituted or unsubstituted alkyl (C1-20) containing H or optionally an (--O--) link, an aryl, alkenyl, cycloalkyl, cycloalkenyl, or arardyl link. Not all linkages of the polynucleotides need to be identical. The above description applies to all polynucleotides mentioned herein, including RNA and DNA.

[0031] In the present invention, the term "primer" refers to a short nucleic acid sequence having a short free 3-terminal hydroxyl group, capable of forming base pairs with a complementary template sequence, and functioning as a starting point for template strand replication; it refers to a single-stranded oligonucleotide complementary to the 5' end sequence and the 3' end sequence adjacent to the target nucleic acid used in the polymerase chain reaction (PCR). Additionally, the terms "forward primer" and "reverse primer" refer to primers that bind to the 3' end and 5' end, respectively, of a specific site of the template amplified by the polymerase chain reaction. The primers can initiate DNA synthesis in the presence of reagents for the polymerization reaction (i.e., DNA polymerate or reverse transcriptase) and four different nucleoside triphosphates at an appropriate buffer solution and temperature. The sequence of the primer does not need to have a sequence that is completely complementary to a part of the template sequence; it is sufficient to have sufficient complementarity within a range where it can hybridize with the template and perform its own function as a primer. Accordingly, the primer set according to one embodiment does not need to have a sequence that is perfectly complementary to the nucleotide sequence of the template; it is interpreted that it is sufficient to have sufficient complementarity within a range where it can hybridize with this sequence and perform its function as a primer.

[0032] In the present invention, the term "hybridization" refers to the process in which two complementary strands of nucleic acids combine to form a double-stranded molecule (hybrid).

[0033] In the present invention, the term "probe" refers to an oligonucleotide, such as RNA or DNA, ranging from a few bases to hundreds of bases in length, capable of forming a specific binding with mRNA, and may be naturally occurring or produced synthetically, recombinantly, or by PCR amplification, and may bind to a minimal portion of another target oligonucleotide. The probe may be single-stranded or double-stranded, and the probe is useful for the detection, definition, and isolation of specific sequences. In a preferred embodiment, the probe used in the present invention may include a fluorescent, radioactive, and luminescent system and may be labeled with a "reporter molecule" so as to be detected by other detection systems.

[0034] In the present invention, the terms “polynucleotide” or “nucleic acid” mean a polymer of nucleotides of any length, including DNA and RNA. The nucleotides may be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or analogs thereof, or any substrate that can be incorporated into a polymer by DNA or RNA. The polynucleotides may include modified nucleotides such as methylated nucleotides and analogs thereof.

[0035] In the present invention, the term “analogous / homologue” is used to refer to a nucleic acid that is distinguished from naturally occurring nucleic acids (e.g., “prototype” or “wild-type” nucleic acids) by slight modifications, while retaining the basic nucleotide structure of the naturally occurring form. Such modifications include, but are not limited to, changes in one or a few nucleotides, including deletions (e.g., truncated versions of nucleic acids), insertions, and / or substitutions. An analogous may have enhanced, reduced, or substantially similar properties compared to the naturally occurring nucleic acid. A homologue may be complementary or identical to the naturally occurring nucleic acid. An analogous may be produced using techniques known in the ordinary art for the production of nucleic acids, including but not limited to recombinant DNA technology and chemical synthesis.

[0036] In the present invention, the term “substantially identical” means that two nucleic acid sequences have at least 70% sequence homology. Preferably, when the sequence of the present invention is aligned with any other sequence to the greatest extent possible and the aligned sequence is analyzed using an algorithm commonly used in the art, it has at least 60% homology, more preferably 70% homology, even more preferably 80% homology, and most preferably 90% sequence homology. Alternatively, “substantially identical” means that two nucleic acid sequences can be hybridized under high-strictness conditions.

[0037] In the present invention, the term “diagnosis” includes determining the susceptibility of a subject to a specific disease or condition, determining whether a subject currently has a specific disease or condition, determining the prognosis of a subject with a specific disease or condition (e.g., determining the stage of a disease caused by a viral infection or determining responsiveness to treatment), or therametrics (e.g., monitoring the subject’s condition to provide information on therapeutic efficacy).

[0038] In one aspect, the present invention relates to a kit for predicting or diagnosing colorectal cancer, comprising a composition for predicting or diagnosing colorectal cancer according to the present invention.

[0039] In one embodiment, the kit may be an RT-PCR kit, a microarray chip or a microfluidic chip, or a biochip, and the biochip may be a DNA chip or an SNP chip.

[0040] In one embodiment, the kit may be a kit containing essential elements necessary for performing DNA chip analysis. A DNA chip kit is a tool that enables large-scale parallel analysis by attaching nucleic acid species in a gridded array to a glass surface, typically not larger than a microscope slide, on a flat solid support plate, so that nucleic acids are arranged uniformly on the chip surface, thereby allowing multiple hybridization reactions to occur between the nucleic acids on the DNA chip and the complementary nucleic acids contained in the solution treated on the chip surface.

[0041] In one embodiment, the kit may include not only the composition for predicting or diagnosing colorectal cancer but also one or more other component compositions, solutions, or devices suitable for the analysis method.

[0042] In one embodiment, the kit may be a kit containing essential elements necessary to perform PCR, and may further include, for example, a pair of primers capable of amplifying a polynucleotide containing an SNP site, a test tube or other suitable container, a reaction buffer (pH and magnesium concentration vary), deoxynucleotides (dNTPs), enzymes such as Taq-polymerase and reverse transcriptase, DNase, an RNAse inhibitor, DEPC-water, and sterile water.

[0043] In one embodiment, the microarray refers to a structure in which polynucleotides are immobilized at a high density in a separated region of a substrate surface. The microarray may be such that the region is arranged on the substrate at a density of, for example, 400 or more / cm², 103 or more / cm², or 104 or more / cm². The microarray of the present invention may be a conventional microarray except that it includes the composition for predicting or diagnosing colorectal cancer development. Hybridization of nucleic acids on a microarray and detection of hybridization results are well known in the art. The detection can be performed, for example, by labeling a nucleic acid sample with a labeling material capable of generating a detectable signal, such as a fluorescent material, for example, Cy3 and Cy5, then hybridizing it on the microarray and detecting the signal generated from the labeling material to detect the hybridization result.

[0044] In one embodiment, the microfluidic chip is a microfluidic device that measures and analyzes the interaction between a target substance contained in a fluid sample and a biomaterial, cell, tissue, or detection device on the chip using microfluidic control technology, and may include processes such as probe / target hybridization, nucleic acid amplification, and capillary electrophoresis reactions by miniaturizing and compartmentalizing them.

[0045] In one embodiment, the kit may include a guide. The guide is a printed document explaining the use of the kit, for example, methods for preparing reverse transcription buffer and PCR buffer, and presented reaction conditions. The guide includes instructions in the form of a pamphlet or leaflet, a label attached to the kit, and on the surface of a package containing the kit. Additionally, the guide includes information disclosed or provided through an electronic medium, such as the Internet.

[0046] In one aspect, the present invention relates to a method for providing information for predicting or diagnosing colorectal cancer, comprising the step of detecting a single nucleotide polymorphism of the MMP14 gene in a biological sample isolated from a target.

[0047] In one embodiment, the single nucleotide polymorphism of the MMP14 gene may be a single nucleotide polymorphism of the dbSNP database rs3751489, and may be the rs3751489 G>A polymorphism corresponding to the 1292nd nucleotide of the nucleotide sequence indicated by SEQ ID NO. 1.

[0048] In one embodiment, the method may further include the step of detecting a single nucleotide polymorphism present in an intron of the MKLN1 gene, wherein the single nucleotide polymorphism may be rs75170436, or rs75170436 T>C or rs75170436 T>G polymorphism.

[0049] In one embodiment, the subject may be a mammal, including a human. The biological sample refers to a sample obtained from a living organism. The biological sample may be, for example, tissue, urine, mucus, saliva, tears, blood, plasma, serum, sputum, cerebrospinal fluid, pleural fluid, nipple aspirate, bone marrow fluid, lymph fluid, airway fluid, serous fluid, genitourinary fluid, breast milk, lymphatic fluid, semen, cerebrospinal fluid, fluid within the organ system, ascites, cystic tumor fluid, amniotic fluid, or a combination thereof.

[0050] In one embodiment, the step of obtaining a nucleic acid sample from a biological sample may be further performed, and this may be performed by a conventional DNA isolation method. For example, the target nucleic acid may be obtained by amplifying it through a polymerase chain reaction (PCR), a ligase chain reaction (LCR), transcription amplification, or real-time-nucleic acid sequence based amplification (NASBA) and purifying it.

[0051] In one embodiment, the step of detecting a single nucleotide polymorphism may include a step of amplifying the single nucleotide polymorphism or hybridizing it with a probe using a polynucleotide containing a nucleic acid that is identical to or complementary to the nucleic acid sequence of a gene in which a single nucleotide polymorphism exists in a biological sample.

[0052] In one embodiment, the step of amplifying the polymorphic site of the single nucleotide polymorphism marker or hybridizing it with a probe can be any method known to a person skilled in the art. For example, the target nucleic acid can be obtained by amplifying it via PCR and purifying it. Other methods may include ligase chain reaction (LCR) (Wu and Wallace, Genomics 4, 560 (1989); Landegren et al., Science 241, 1077 (1988)), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86, 1173 (1989)), self-maintaining sequence replication (Guatelli et al., Proc. Natl. Acad. Sci. USA 87, 1874 (1990)), and nucleic acid-based sequence amplification (NASBA).

[0053] In one embodiment, the step of detecting a single nucleotide polymorphism may be performed by a polymerase chain reaction (PCR), a molecular beacon, a primer extension, or a combination thereof.

[0054] In one embodiment, the method may further include the step of determining the base of the detected SNP site.

[0055] In one embodiment, when the genotype of the single nucleotide polymorphism rs3751489 of the MMP14 gene is adenine, it can be predicted that there is a high risk of developing colorectal cancer.

[0056] In one embodiment, if the genotype of rs75170436 of the MKLN1 gene is cytosine or guanine, it can be predicted that there is a high risk of developing colorectal cancer.

[0057] In one embodiment, the step of determining the base of the detected SNP site may be performed using electrophoresis, sequencing analysis, microarray hybridization, allele-specific PCR, dynamic allele-specific hybridization (DASH), PCR extension analysis, PCR-SSCP, PCR-RFLP analysis, HRM analysis or TaqMan technique, SNPlex platform (Applied Biosystems), mass spectrometry (e.g., Sequenom’s MassARRAY system), mini-sequencing method, Bio-Plex system (BioRad), CEQ and SNPstream system (Beckman), molecular inversion probe array technology (e.g., Affymetrix GeneChip), and BeadArray Technologies (e.g., Illumina GoldenGate and Infinium analysis methods).

[0058] In the present invention, the term "risk" indicates that the frequency of occurrence of a disease or condition in an individual possessing a specific single nucleotide polymorphism is statistically higher compared to the frequency of occurrence of the disease or condition in members of an individual not possessing the specific single nucleotide polymorphism.

[0060] The present invention will be explained in more detail through the following examples. However, the following examples are intended only to illustrate the content of the present invention and do not limit the present invention.

[0062] Example 1. Recruitment of colorectal cancer patients and prospective follow-up

[0063] To identify SNPs associated with colorectal cancer, 960 patients with follow-up data for a genome-wide association study (GWAS) on genome-wide SNPs (single-nucleotide polymorphisms) and CRC survival were selected (IRB No. 1906-116-1041, 1908-094-1055). These patients underwent surgical treatment at SNUH (Seoul National University Hospital) between May 2014 and June 2017 and were prospectively followed up until April 14, 2023 (follow-up period, median = 61.4 months, range = 1-96 months). For the control group GWAS, the KoGES (Korean Genome and Epidemiology Study) population was used as the control group, identical to the covariate of the CRC patients at SNUH. Prior to matching the KOGES group (control group) and the CRC group (case group), each group was divided into the following five subgroups based on patient age: 50 to 55, 55 to 60, 60 to 65, 65 to 70, and 70 to 75. Since previous studies showed that the risk of colorectal cancer increased with age, the study population was strictly stratified to eliminate the influence of age. After stratification, the control and case groups were matched according to age categories. The number of participants in each group used in the discovery study was 50 for the case group and 150 for the control group (Table 1), while the ratio of the case group to the control group in the replication study was approximately 1:10 (Table 2). Regarding the age of the study population, the case group showed an average age of 63.0 years and a standard deviation of 7.15 years, while the control group showed an average age of 62.9 years and a standard deviation of 7.07 years. P-The value is 0.954, indicating that the distribution between the control and case groups is not statistically significant. In terms of gender distribution, both the case and control groups showed a balanced mix of men and women. Additionally, the smoking history and drinking history variables were 0.226 and 0.394, respectively. P- The value was expressed, confirming that there was no statistical significance.

[0064]

[0065]

[0067] Example 2. Screening and Validation of Patient-Derived SNPs

[0068] SNP regions were extracted from the blood-derived genome of the above patient by performing an analysis based on the Korean Biobank. Specifically, in the matching dataset of the KoGES and CRC patient groups, Minor Allele Frequency (MAF) < 0.01, Hardy-Weinberg Equilibrium (HWE) P- value < 1.00×10 -6 409,063 SNPs were selected by applying four exclusion criteria, including a call rate of 98%. Additionally, SNUH GWAS data was imputed to the Michigan Imputation Server using MINIMAC 4 software; 1,000 genomes were selected as a reference panel, and since the SNUH GWAS data includes only Korean data, the subgroup was set to East Asia. For QC of the results, the rsq (r-squared statistic) filter value was set to 0.3 to remove more than 70% of SNPs, and the standard QC settings of the Michigan Imputation Server—MAF (minor-allele frequency) < 1%, call rate > 90%, and removal of duplicate SNPs—were executed.

[0069] As a result, 2,514 SNPs were excluded from the imputed dataset due to invalid alleles (942 SNPs) and allele mismatches (1,503 SNPs), and the remaining 7,835,640 SNPs were selected.

[0071] Example 3. Screening of SNPs associated with colorectal cancer risk

[0072] 3-1. Statistical Analysis of SNP Risk of Colorectal Cancer Development

[0073] Beta values ​​were calculated using logistic regression based on single nucleotide polymorphisms. Specifically, for the discovery study, categorical BMI, age, and sex were selected as covariates using plink software and consistently applied to CRC patients (case group) and KoGES (control group). For the outcome variable, the control group was assigned a value of 0 and the case group a value of 1. Additionally, the significant SNPs identified in the discovery study were used in a replication study using CRC patients from Chonnam National University Hospital as the case group and the KoGES group as the control group. P- The value threshold for the discovery study is 5.00 × 10⁻⁶ -8 The GWAS P-value was set to 0.05, and the replication study was set to 0.05. Confounding factors were used identically in both studies. Additionally, the 'meta' R package was executed for meta-analysis, and from the meta-analysis results P- Value and I 2 Values ​​are extracted, and since the control groups of the discovery study and replication study belong to the same demographic, a fixed effect is used to interpret the analysis results. P-Effect P-values ​​were used. In addition, Manhattan plots of significant SNPs associated with clinical outcomes were generated using the 'CMplot' R package. Cut-off P- Values ​​and significant SNPs were indicated in distinct colors. In addition, to distinguish between SNPs in the linkage disequilibrium (LD) closely located on each chromosome and independent index SNPs, pairwise LD analysis was performed, and the LDmatrix function of the LDlink web-based service was used to r 2 The values ​​were calculated, the genome build was set to GRCh38, and the sub-population was designated as East Asia. Subsequently, r on each chromosome 2 The lowest among SNPs with a value of 0.6 or higher P- SNPs with values ​​were selected.

[0074]

[0075] (SNP: single nucleotide polymorphism; Chr: chromosome; Pos: position; Ref: reference allele; Alt: alteration allele; B: Beta value; P : P- value; P het : heterogenous P- value; Func: functionality; int: intronic; exo:exonic; down: downstream; and inter: intergenic.)

[0076] As a result of the discovery study, 106 SNPs were found, totaling 5.00 × 10⁶ -8 Below the threshold P- The values ​​were shown (Fig. 2). As a result of utilizing this in a replication study, 40 SNPs were below a threshold of 0.05. P-The value was presented. A meta-analysis was performed using the above 40 SNPs, yielding 5.00 × 10⁻⁶ -8 Meta-analysis below the threshold P- 14 SNPs with values ​​were selected, and 4 SNPs of LD were removed (Table 3).

[0078] 3-2. Analysis of Functional Mapping and Annotation of GWAS

[0079] To extend the statistical analysis results of Example 3-1 above, FUMA GWAS (Functional Mapping and Annotation of Genome-Wide Association Studies) was used. rsID and meta-analysis for each SNP. P- Upload the GWAS summary statistics of the values, and the maximum of lead SNPs in the SNP identification step P- The value is 5.00×10 -8 Lo, maximum P- The value cutoff was set to 0.05. Also, the 1st r 2 threshold and second r 2 Independent significant SNPs were defined using threshold values ​​of 0.6 and 0.1, respectively, and the 1000G Phase3 EAS (east Asians) group was selected for the reference panel population. Subsequently, in a location map meta-analysis considering a maximum distance of 10 kb between the SNP and its corresponding gene, rs75170436 (7q32.3, MKLN1 , Beta=-0.95, P- value=3.79×10⁻⁹, CADD score=15.52) is 0.00% I 2 Value and 5.90×10 -18 meta-analysis of P- Represented the value, rs3751489 (14q11.2, MMP14 , Beta=-2.57, P- value=3.01×10 -8 , CADD score=32) is 79.96% of I 2 Value and 2.31×10 -12 meta-analysis of P-The values ​​were presented. Gene annotation was performed using positional mapping that considered a maximum distance of 10kb between the SNP and its corresponding gene. Additionally, the Combined Dependent Depletion (CADD) framework was used to filter out variants with a PHRED score (-10*log(rank / total)) exceeding 12.47; for scores of 10 or higher, 10% were expected to contain deleterious substitutions, and for scores of 20 or higher, 1% were expected to contain deleterious substitutions. Furthermore, the Annotation RegulomeDB was used to filter SNPs, and the analysis focused on regulatory elements within their established and predicted intergene regions. Variants were classified on a scale of 1 to 7, with lower scores indicating higher regulatory significance.

[0080] As a result, rs3751489 showed notable results in FUMA GWAS, but heterogeneity was not realized (Table 3). On the other hand, rs75170436 showed significant results in FUMA GWAS and heterogeneity (Table 3). In particular, both SNPs showed significant CADD score results in FUMA GWAS. Thus, it was confirmed that rs75170436 has the top 10% of harmful substitutions, and rs3751489 has the top 1% of harmful substitutions. Aside from these two SNPs, no other SNPs showed notable CADD scores. Furthermore, similar to the above, the analysis of the RegulomeDB (RDB) showed that rs75170436 had an RDB score of 4 and rs3751489 had an RDB score of 3a (Table 3). This confirmed that rs75170436 possesses minimal evidence of binding with the DNase peak of the transcription factor (TF), while rs3751489 is less likely to affect the binding of the DNase peak with the TF and DNase peaks, as well as all other peaks. Aside from these two SNPs, there were no other SNPs with an RDB score of 4 or lower. Additionally, in the FUMA GWAS analysis, rs75170436 was identified as an intron and rs3751489 as an exon; thus, rs75170436 MKLN1 While it is predicted that it will not directly affect the protein product, rs3751489 mutates from reference allele G to allele A, so directly MMP14 It was predicted that it would affect the structure and function of the protein product of (matrix metalloproteinase-14). Therefore, it was inferred that rs3751489 would have a more significant effect on colorectal cancer risk compared to rs75170436.

[0082] 3-3. Biological Analysis

[0083] The expression profiles of specific genes matched with the SNPs selected in the above example were analyzed in the sigmoid colon and transverse colon using the GTEx (Genotype-Tissue Expression) portal. GTEx was used to generate associations between genotype and gene expression by deciphering how genetic variation affects gene activity in various human tissues, and TPM (Transcripts Per Million) was used as a normalization method to adjust RNA sequencing data for both gene length and library size to generate expression measurements suitable for comparison between samples and to distinguish genes expressed in various tissues.

[0084]

[0085] As a result of GTeX analysis, the gene matched with SNP rs3751489 selected from the FUMA GWAS analysis results of the above example MMP14 It was found that the gene had significantly higher TPM values ​​compared to other genes in both colon tissues (Fig. 3 and Table 4).

[0087] Based on the above results, rs3751489 was selected as a susceptibility SNP associated with the development of colorectal cancer (CRC).

Claims

Claim 1 A marker composition for predicting or diagnosing colorectal cancer, comprising a single-nucleotide polymorphism (SNP) of the MMP14 (matrix metalloproteinase-14) gene. Claim 2 A marker composition for predicting or diagnosing colorectal cancer, wherein the single nucleotide polymorphism of the MMP14 gene in claim 1 is rs3751489. Claim 3 A marker composition for predicting or diagnosing colorectal cancer, wherein, in claim 2, the single nucleotide polymorphism of the MMP14 gene is the rs3751489 G>A polymorphism corresponding to the 1292nd nucleotide of the nucleotide sequence indicated by SEQ ID NO.

1. Claim 4 A marker composition for predicting or diagnosing colorectal cancer development, wherein, in claim 1, the single nucleotide polymorphism rs75170436 of the MKLN1 (muskelin 1) gene is further included. Claim 5 A composition for predicting or diagnosing colorectal cancer development comprising a preparation capable of detecting or amplifying a single nucleotide polymorphism of the MMP14 gene. Claim 6 A composition for predicting or diagnosing colorectal cancer development, wherein, in claim 5, the single nucleotide polymorphism of the MMP14 gene is the rs3751489 G>A polymorphism corresponding to the 1292nd nucleotide of the nucleotide sequence represented by SEQ ID NO.

1. Claim 7 In claim 5, the composition for predicting or diagnosing colorectal cancer development comprises a probe or primer capable of detecting or amplifying a polynucleotide containing a single base polymorphism or a polynucleotide complementary thereof. Claim 8 In claim 5, the preparation capable of detection or amplification is a probe or primer comprising a polynucleotide consisting of 8 to 100 consecutive nucleotides including the 1292nd nucleotide of the nucleotide sequence represented by SEQ ID NO. 1 or a polynucleotide complementary thereof, or a microarray comprising a polynucleotide consisting of 8 to 100 consecutive nucleotides including the 1292nd nucleotide of the nucleotide sequence represented by SEQ ID NO. 1 or a polypeptide encoded by the same or its cDNA, a composition for predicting or diagnosing the development of colorectal cancer. Claim 9 A composition for predicting or diagnosing colorectal cancer development, further comprising a preparation capable of detecting or amplifying the single nucleotide polymorphism rs75170436 of the MKLN1 gene in claim 5. Claim 10 A kit for predicting or diagnosing colorectal cancer development comprising the composition of claim 5. Claim 11 A method for providing information for predicting or diagnosing colorectal cancer, comprising the step of detecting a single nucleotide polymorphism of the MMP14 gene in a biological sample isolated from a target. Claim 12 A method for providing information for predicting or diagnosing the development of colorectal cancer, wherein the biological sample is tissue, urine, mucus, saliva, tears, blood, plasma, serum, sputum, cerebrospinal fluid, pleural fluid, nipple aspirate, bone marrow fluid, lymph fluid, airway fluid, serous fluid, genitourinary fluid, breast milk, lymphatic fluid, semen, cerebrospinal fluid, intra-organ fluid, ascites, cystic tumor fluid, amniotic fluid, or a combination thereof. Claim 13 A method for providing information for predicting or diagnosing colorectal cancer, wherein the step of detecting a single nucleotide polymorphism comprises a step of amplifying the single nucleotide polymorphism or hybridizing it with a probe using a polynucleotide containing a nucleic acid that is identical to or complementary to the nucleic acid sequence of a gene in which a single nucleotide polymorphism exists in a biological sample. Claim 14 A method for providing information for predicting or diagnosing colorectal cancer, wherein the step of detecting a single nucleotide polymorphism is performed by a polymerase chain reaction (PCR), a molecular beacon, a primer extension, or a combination thereof. Claim 15 A method for providing information for predicting or diagnosing colorectal cancer, wherein, in claim 11, the single nucleotide polymorphism of the MMP14 gene is the rs3751489 G>A polymorphism corresponding to the 1292nd nucleotide of the nucleotide sequence indicated by SEQ ID NO.

1. Claim 16 A method for providing information for predicting or diagnosing the development of colorectal cancer, wherein the genotype of rs3751489 is adenine, and the risk of developing colorectal cancer is predicted to be high. Claim 17 A method for providing information for predicting or diagnosing colorectal cancer, wherein, in claim 11, the step of detecting a single nucleotide polymorphism rs75170436 of the MKLN1 gene is further included. Claim 18 A method for providing information for predicting or diagnosing the development of colorectal cancer, wherein the genotype of rs75170436 is cytosine or guanine, and the risk of developing colorectal cancer is predicted to be high.